Leprosy (Hansen’s Disease)

  • Clio DessiniotiEmail author
  • Andreas D. Katsambas


Leprosy is a chronic granulomatous bacterial infection caused by the bacillus Mycobacterium leprae (M.leprae) that primarily affects the skin and peripheral nerves. Leprosy is a multi-organ infectious disease that can cause severe disability. Lepromatous leprosy is considered to be at the systemic and infectious end of the disease spectrum and correlates with an absence of an immune response to M. leprae antigens. Tuberculoid leprosy form correlates with adequate immune response, lesions are not usually large or numerous and it may resolve spontaneously. Multidrug therapy treatment is a highly effective cure for leprosy. Leprosy may be complicated by episodes of immunological instability including type-1 and type-2 reactions (erythema nodosum leprosum).


Leprosy Hansen’s disease Mycobacterium leprae Multidrug therapy Erythema nodosum leprosum 

Further Reading

  1. Chander R, Jabeen M, Malik M. Molluscum contagiosum-like lesions in histoid leprosy in a 10-year old boy. Pediatr Dermatol. 2013;30:e261–2.CrossRefGoogle Scholar
  2. Deps P, Lucas S, Porro AM, et al. Clinical and histological features of leprosy and human immunodeficiency virus co-infection in Brazil. Clin Dermatol. 2013;38:470–7.CrossRefGoogle Scholar
  3. Eichenlmann K, Gonzales Gonzales SE, Salas-Alanis JC, Ocampo-Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis and treatment. Actas Dermosifiliogr. 2013;104:554–63.CrossRefGoogle Scholar
  4. Grant AV, Cobat A, Van Thuc N, et al. CUBN and NEBL common variants in the chromosome 10p13 linkage region are associated with multibacillary leprosy in Vietnam. Hum Genet. 2014;133(7):883–93. PMID: 24563210.PubMedGoogle Scholar
  5. Hansen GHA. Undersøgelser Angående Spedalskhedens Årsager (investigations concerning the etiology of leprosy). Norsk Mag Laegervidenskaben. 1874;4:1–88.Google Scholar
  6. Jakeman P, Smith WCS. Thalidomide in leprosy reaction. Lancet. 1994;343:432–3.CrossRefGoogle Scholar
  7. Kaur I, Dogra S, De D, et al. Histoid leprosy: a retrospective study of 40 cases from India. Br J Dermatol. 2009;160:305–10.CrossRefGoogle Scholar
  8. Merle CSC, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines. 2010;9:209–22.CrossRefGoogle Scholar
  9. National Leprosy Elimination Program (NLEP) India. Modified guidelines on MDT regimens to be followed under NLEP. New Delhi: Leprosy Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 1997.Google Scholar
  10. Ridley D, Jopling W. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34:255–73.PubMedGoogle Scholar
  11. Silva GAV, Naveca FG, Ramasawmy R, et al. Association between the IFN-γ +874A/T gene polymorphism and leprosy resistance: a meta-analysis. Cytokine. 2014;65:130–3.CrossRefGoogle Scholar
  12. Voorend CGN, Post EB. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis. 2013;7:e2440.CrossRefGoogle Scholar
  13. WHO. Global leprosy situation. Wkly Epidemiol Rec. 2012;87:317–28.Google Scholar
  14. WHO MDT: duration of treatment. Accessed 1 Apr 2014.
  15. WHO recommended MDT regimens. Accessed 1 Apr 2014.
  16. WHO. Chemotherapy of leprosy. Accessed 1 Apr 2014.
  17. WHO. Leprosy today. Accessed 1 Apr 2014.

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of DermatologyAndreas Syggros Hospital, University of AthensAthensGreece
  2. 2.1st Department of Dermatology and VenereologyUniversity of Athens School of Medicine, “A. Sygros” Hospital for Skin and Venereal DiseasesAthensGreece

Personalised recommendations